These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 21554907)

  • 1. Focus.
    Shouval D
    J Hepatol; 2011 Aug; 55(2):243-4. PubMed ID: 21554907
    [No Abstract]   [Full Text] [Related]  

  • 2. Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis.
    Patsenker E; Schneider V; Ledermann M; Saegesser H; Dorn C; Hellerbrand C; Stickel F
    J Hepatol; 2011 Aug; 55(2):388-98. PubMed ID: 21168455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Everolimus: a new mammalian target of rapamycin inhibitor for the treatment of advanced renal cell carcinoma.
    Grgic T; Mis L; Hammond JM
    Ann Pharmacother; 2011 Jan; 45(1):78-83. PubMed ID: 21177421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus: a guide to its use in liver transplantation.
    Keating GM; Lyseng-Williamson KA
    BioDrugs; 2013 Aug; 27(4):407-11. PubMed ID: 23696253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Late conversion to mammalian target of rapamycin inhibitor/proliferation signal inhibitors in kidney transplant patients: clinical experience in the last 5 years.
    Sola E; Lopez V; Gutierrez C; Cabello M; Burgos D; Molina MG; Hernandez D
    Transplant Proc; 2010 Oct; 42(8):2859-60. PubMed ID: 20970551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Everolimus interferes with the inflammatory phase of healing in experimental colonic anastomoses.
    Küper MA; Schölzl N; Traub F; Mayer P; Weinreich J; Coerper S; Steurer W; Königsrainer A; Beckert S
    J Surg Res; 2011 May; 167(1):158-65. PubMed ID: 19922952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Everolimus and azoospermia, a causal relationship? About one case in a renal transplant patient].
    Wetzstein M; Weestel PF; Choukroun G
    Nephrol Ther; 2014 Feb; 10(1):44-5. PubMed ID: 24374233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Long Journey of mTOR Inhibitors and the Long Path That Is Still Ahead.
    Tedesco Silva H
    Transplantation; 2018 Feb; 102(2S Suppl 1):S1-S2. PubMed ID: 29369969
    [No Abstract]   [Full Text] [Related]  

  • 9. Everolimus and giant-cell astrocytomas in tuberous sclerosis.
    Jia J; Xiong L; Chen S
    N Engl J Med; 2011 Feb; 364(6):577. PubMed ID: 21306252
    [No Abstract]   [Full Text] [Related]  

  • 10. TOR-inhibitors as gero-suppressors.
    Nikiforov M
    Aging (Albany NY); 2015 Dec; 7(12):1030-1. PubMed ID: 26796970
    [No Abstract]   [Full Text] [Related]  

  • 11. mTOR inhibition in T-cell lymphoma: a path(way) forward.
    Moskowitz AJ; Horwitz SM
    Blood; 2015 Jul; 126(3):284-6. PubMed ID: 26185115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everolimus-related organizing pneumonia: a report establishing causality.
    Frija J; Joly D; Knebelmann B; Dusser D; Burgel PR
    Invest New Drugs; 2012 Jun; 30(3):1244-7. PubMed ID: 21188465
    [No Abstract]   [Full Text] [Related]  

  • 13. Lack of efficacy of mTOR inhibitors and ACE pathway inhibitors as antifibrotic agents in evolving and established fibrosis in Mdr2⁻/⁻ mice.
    Bridle KR; Sobbe AL; de Guzman CE; Santrampurwala N; Jaskowski LA; Clouston AD; Campbell CM; Nathan Subramaniam V; Crawford DH
    Liver Int; 2015 Apr; 35(4):1451-63. PubMed ID: 24517519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus.
    Sánchez-Fructuoso AI; Ruiz JC; Pérez-Flores I; Gómez Alamillo C; Calvo Romero N; Arias M
    Transplant Proc; 2010 Oct; 42(8):3050-2. PubMed ID: 20970607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic use of mTOR inhibitors and other immunosuppressive agents in heart transplant patients.
    Santoni M; Massari F; Cascinu S
    Cell Mol Immunol; 2015 Jan; 12(1):122-4. PubMed ID: 24882385
    [No Abstract]   [Full Text] [Related]  

  • 16. The mTORC pathway in the antiphospholipid syndrome.
    Eikelboom JW; Weitz JI
    N Engl J Med; 2014 Jul; 371(4):369-71. PubMed ID: 25054721
    [No Abstract]   [Full Text] [Related]  

  • 17. Everolimus and giant-cell astrocytomas in tuberous sclerosis.
    Nawashiro H; Shinomiya N
    N Engl J Med; 2011 Feb; 364(6):576-7; author reply 577. PubMed ID: 21306253
    [No Abstract]   [Full Text] [Related]  

  • 18. Inhibition of the mTORC pathway in the antiphospholipid syndrome.
    Hidalgo LG
    N Engl J Med; 2014 Oct; 371(16):1554. PubMed ID: 25317880
    [No Abstract]   [Full Text] [Related]  

  • 19. Inhibition of the mTORC pathway in the antiphospholipid syndrome.
    Zuily S; Regnault V; Wahl D
    N Engl J Med; 2014 Oct; 371(16):1553-4. PubMed ID: 25317879
    [No Abstract]   [Full Text] [Related]  

  • 20. Inhibition of the mTORC pathway in the antiphospholipid syndrome.
    Van Laecke S; Nagler EV; Vanholder R
    N Engl J Med; 2014 Oct; 371(16):1553. PubMed ID: 25317878
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.